摘要
目的探讨在直肠癌术后化疗中应用注射用辅酶Ⅰ对预防患者白细胞减少的临床效果。方法按照随机数字表法将82例直肠癌术后化疗患者随机分为联合组和常规组,每组41例。常规组接受常规直肠癌化疗,联合组在常规化疗的基础上接受注射用辅酶Ⅰ治疗。治疗结束后,记录两组患者的中性粒细胞和白细胞计数,比较两组患者的不良反应发生情况。结果化疗第1周期的第4天,联合组患者中性粒细胞和白细胞减少的发生率均明显低于常规组(P<0.01)。化疗第2周期的第1、4天,联合组患者中性粒细胞和白细胞减少的发生率均低于常规组(P<0.05)。化疗第2周期的第1天,两组患者2级以上中性粒细胞和白细胞减少的发生率比较,差异均无统计学意义(P>0.05)。化疗第2周期的第4天,常规组患者的2级以上中性粒细胞和白细胞减少的发生率均高于联合组(P<0.05)。治疗后,两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论注射用辅酶Ⅰ可有效预防直肠癌化疗引发的白细胞减少,安全性较高。
Objective To study the clinical effect of coenzyme for injection in preventing leukopenia in patients undergoing postoperative chemotherapy for rectal cancer.Method 82 patients with rectal cancer undergoing postoperative chemotherapy were randomly divided into the combined group and the conventional group according to the random number table method,with 41 patients in each group.Conventional group received conventional colorectal cancer chemotherapy,combined group on the basis of conventional chemotherapy received coenzyme I for injection treatment.After treatment,the degree of neutropenia and leukopenia and adverse reactions were compared between the two groups.Result On the fourth day after the first cycle of chemotherapy,the incidence rate of neutropenia and leucopenia in the combined group was significantly lower than that in the conventional group(P<0.01).On the first and fourth days of the second cycle of chemotherapy,the incidence rate of neutropenia and leucopenia in the combination group was lower than that in the conventional group(P<0.05).On the first day of the second cycle of chemotherapy,there was no significant difference in the incidence rate of neutropenia and leucopenia above grade 2 between the two groups(P>0.05).On the fourth day of the second cycle of chemotherapy,the incidence rate of neutropenia and leucopenia in the conventional group were higher than those in the combination group(P<0.05).The total incidence of adverse reactions between the two groups was not statistically significant(P>0.05).Conclusion Coenzyme for injection can effectively prevent leukopenia after chemotherapy for rectal cancer and has high safety.
作者
沙粒
杜磊
刘岗
张浩
SHA Li;DU Lei;LIU Gang;ZHANG Hao(Department of General Surgery,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200000,China)
出处
《癌症进展》
2020年第13期1370-1372,1387,共4页
Oncology Progress
基金
中医优势病种培育建设项目(ZY(2018-2020)-ZYBZ-07)。